Semaglutide
From Proteopedia
(Difference between revisions)
| Line 3: | Line 3: | ||
==Discovery== | ==Discovery== | ||
| - | Semaglutide was discovered <ref>PMID:26308095/ref> in an effort to increase the lifetime of a once-a-day medication called Liraglutide. It is derived from the GLP-1 hormone, contains two amino acid sequence changes and a covalently attached lipid. | + | Semaglutide was discovered <ref>PMID:26308095</ref> in an effort to increase the lifetime of a once-a-day medication called Liraglutide. It is derived from the GLP-1 hormone, contains two amino acid sequence changes and a covalently attached lipid. |
==Structure and Receptor Binding== | ==Structure and Receptor Binding== | ||
Revision as of 15:07, 26 October 2024
Semaglutide is an analog of the GLP-1 (glucagon-like peptide-1) hormone. It acts as an agonist to the GLP-1 receptor and is used as drug to manage diabetes. Its use has been growing as a weight-loss medication, and potential benefits across a wide range of diseases is currently studied.
Discovery
Semaglutide was discovered [1] in an effort to increase the lifetime of a once-a-day medication called Liraglutide. It is derived from the GLP-1 hormone, contains two amino acid sequence changes and a covalently attached lipid.
Structure and Receptor Binding
| |||||||||||
References
- ↑ Lau J, Bloch P, Schaffer L, Pettersson I, Spetzler J, Kofoed J, Madsen K, Knudsen LB, McGuire J, Steensgaard DB, Strauss HM, Gram DX, Knudsen SM, Nielsen FS, Thygesen P, Reedtz-Runge S, Kruse T. The discovery of the once weekly glucagon like peptide 1 (GLP-1) analog semaglutide. J Med Chem. 2015 Aug 26. PMID:26308095 doi:http://dx.doi.org/10.1021/acs.jmedchem.5b00726
